Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Recommendation of “Hold” by Brokerages

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have earned an average rating of “Hold” from the thirty brokerages that are covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a sell recommendation, fifteen have given a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $33.68.

A number of research analysts have weighed in on SRPT shares. Bank of America upped their price objective on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the stock an “underperform” rating in a research report on Wednesday, October 22nd. Leerink Partners lifted their price target on Sarepta Therapeutics from $12.00 to $15.00 and gave the company a “market perform” rating in a research note on Tuesday, September 9th. Wells Fargo & Company reduced their price target on Sarepta Therapeutics from $50.00 to $45.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Wall Street Zen lowered Sarepta Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Finally, Royal Bank Of Canada boosted their price objective on Sarepta Therapeutics from $14.00 to $16.00 and gave the company a “sector perform” rating in a research report on Wednesday, October 8th.

Sarepta Therapeutics Trading Up 3.5%

Shares of NASDAQ:SRPT opened at $22.31 on Wednesday. The company has a current ratio of 2.95, a quick ratio of 1.79 and a debt-to-equity ratio of 0.78. Sarepta Therapeutics has a 12-month low of $10.41 and a 12-month high of $129.84. The business has a 50 day moving average of $20.88 and a two-hundred day moving average of $20.64. The company has a market capitalization of $2.34 billion, a PE ratio of -7.41 and a beta of 0.54.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.15). Sarepta Therapeutics had a negative net margin of 11.25% and a negative return on equity of 4.85%. The firm had revenue of $399.36 million for the quarter, compared to analysts’ expectations of $331.51 million. During the same period last year, the firm earned $0.62 earnings per share. Sarepta Therapeutics’s revenue for the quarter was down 14.5% compared to the same quarter last year. As a group, analysts forecast that Sarepta Therapeutics will post 2.67 EPS for the current year.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of large investors have recently added to or reduced their stakes in SRPT. Ancora Advisors LLC grew its position in shares of Sarepta Therapeutics by 150.0% in the first quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 300 shares during the period. Brooklyn Investment Group raised its position in shares of Sarepta Therapeutics by 450.4% in the first quarter. Brooklyn Investment Group now owns 721 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 590 shares during the last quarter. Banque Transatlantique SA purchased a new position in Sarepta Therapeutics in the 1st quarter worth approximately $44,000. iSAM Funds UK Ltd acquired a new stake in shares of Sarepta Therapeutics in the third quarter valued at approximately $25,000. Finally, Byrne Asset Management LLC purchased a new position in Sarepta Therapeutics during the third quarter worth approximately $33,000. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.